Instylla published the HES Hypervascular Tumor Study, which reported additional observations on single agent embolization in more than 96% of cases in the Embrace HES arm versus more than 60% in the SOC arm, 40% fewer additional embolization procedures in the Embrace HES arm beyond 90-day follow-up, a disease control rate greater than 90% at 90 days across all lesions, and no clinically significant non-target embolization associated with Embrace HES in 148 treated vessels.